Skip to content

Artiva Biotherapeutics, Inc. ARTV Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
10M0.0%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
10M0.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10M0.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
5M
Immunovant, Inc. logo
Immunovant, Inc.IMVT
10M

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s convertible preferred stock authorized shares?
Artiva Biotherapeutics, Inc. (ARTV) reported convertible preferred stock authorized shares of 10M in Q3 2024.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.